Peptide May Prevent Diabetes

Article

NEW YORK- In a report published in Nature Immunology, officials from Mount Sinai School of Medicine in New York state a soluble dimeric peptide-major histocompatibility complex chimera called DEF prevents the onset of type 1 diabetes in mice.

The mice, prone to the disease, were treated with DEF every 5 days. Ten of the 12 mice in the experiment resisted development of the disease for 4.5 months during the testing. Once the DEF injections halted, however, the mice developed diabetes within 15 days.

DEF is constructed on an immunoglobulin scaffold to bind to cognate T cells.

Information from Given Imaging

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.